Andrew Schally | |
---|---|
Born | Andrzej Viktor Schally 30 November 1926 |
Nationality | Polish [1] [2] Canadian American [3] |
Education | McGill University |
Medical career | |
Profession | Medicine |
Institutions | |
Sub-specialties | Endocrinology |
Awards |
|
Andrzej Viktor "Andrew" Schally (born 30 November 1926) is an American endocrinologist [1] of Polish [1] [2] [4] ancestry, who was a corecipient, with Roger Guillemin and Rosalyn Sussman Yalow, of the Nobel Prize in Physiology or Medicine. [2] This award recognized his research in the discovery that the hypothalamus controls hormone production and release by the pituitary gland, which controls the regulation of other hormones in the body. [5] Later in life, Schally utilized his knowledge of hypothalamic hormones to research possible methods for birth control and cancer treatment.
Andrzej Wiktor Schally [6] was born in Wilno in the Second Polish Republic [1] [2] [4] (now Vilnius, Lithuania), the son of Brigadier General Kazimierz Schally, who was chief of the cabinet of President Ignacy Mościcki of Poland, and Maria (née Łącka).
In September 1939, when Poland was attacked by Nazi Germany and the Soviet Union, Schally escaped with Poland's President Ignacy Mościcki, the prime minister and the whole cabinet to the neutral Romania, where they were interned [ citation needed ].
I was fortunate to survive the holocaust while living among the Jewish-Polish Community in Roumania. I used to speak Polish, Roumanian, Yiddish, Italian and some German and Russian, but I have almost completely forgotten them, and my French in which I used to excel is also now far from fluent. [2]
Immediately after the war, in 1945, Schally moved via Italy and France to the United Kingdom [2] where he changed his first name to Andrew. [6] Schally received his education in Scotland and England. [2] In 1952, he moved to Canada. He received his doctorate in endocrinology from McGill University in 1957. [2] That same year he left for a research career in the United States where he has worked principally at Tulane University. [2] Schally currently conducts research in endocrinology at the Miami Veteran's Administration Medical Center in Miami, Florida.[ citation needed ] A Canadian citizen when he left Canada, Schally became a naturalized citizen of the United States in 1962. [2] He was affiliated with the Baylor College of Medicine for some years in Houston, Texas. [2]
Schally developed a new realm of knowledge concerning the brain's control over the body chemistry. Schally explained in his 1977 Nobel Lecture that he, alongside his researchers, dissected 250,000 pig hypothalami in order to isolate 5 mg of the hormone thyrotropin-releasing hormone (TRH) to determine the molecular structure of the hormone. [7] His work also addressed birth control methods and the effects of growth hormones on the body. Together with Roger Guillemin he described the neurohormone gonadotropin-releasing hormone (GnRH) that controls follicle-stimulating hormone (FSH) and luteinizing hormone (LH), two hormones that are integral parts of reproduction and growth and development.
Schally received an honoris causa doctors degree from the Jagiellonian University in Kraków.
Recognized as a Fellow of the Kosciuszko Foundation of Eminent Scientists of Polish Origin and Ancestry. [8]
Schally was married to Margaret Rachel White (divorced), and Ana Maria de Medeiros-Comaru. [4]
In 1981 it was demonstrated that the gonadotropin-releasing hormone (GnRH) agonistic analogs that Schally had developed between the years of 1972-1978 inhibited the growth of prostate cancer in rats. Alongside Dr. George Tolis, Schally conducted the first clinical trial of GnRH for patients with advanced prostate cancer in 1982. This method is now the preferred treatment for advanced prostate carcinoma. About 70% of patients with prostate cancer receive an agonist as their primary method of treatment. [7] According to Schally, his treatment causes fewer side effects than radiation and chemotherapy. [7] The previous method of treatment, orchiectomy or the administration of estrogens, was based on the research of Charles Brenton Huggins.
In 2004, after the death of his wife due to thyroid cancer, Schally found comfort in continuing his research. [7]
Thyrotropin-releasing hormone (TRH) is a hypophysiotropic hormone produced by neurons in the hypothalamus that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary.
Gonadotropin-releasing hormone (GnRH) is a releasing hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is a tropic peptide hormone synthesized and released from GnRH neurons within the hypothalamus. The peptide belongs to gonadotropin-releasing hormone family. It constitutes the initial step in the hypothalamic–pituitary–gonadal axis.
Kallmann syndrome (KS) is a genetic disorder that prevents a person from starting or fully completing puberty. Kallmann syndrome is a form of a group of conditions termed hypogonadotropic hypogonadism. To distinguish it from other forms of hypogonadotropic hypogonadism, Kallmann syndrome has the additional symptom of a total lack of sense of smell (anosmia) or a reduced sense of smell. If left untreated, people will have poorly defined secondary sexual characteristics, show signs of hypogonadism, almost invariably are infertile and are at increased risk of developing osteoporosis. A range of other physical symptoms affecting the face, hands and skeletal system can also occur.
Goserelin, sold under the brand name Zoladex among others, is a medication which is used to suppress production of the sex hormones, particularly in the treatment of breast and prostate cancer. It is an injectable gonadotropin releasing hormone agonist.
Roger Charles Louis Guillemin is a French-American neuroscientist. He received the National Medal of Science in 1976, and the Nobel prize for medicine in 1977 for his work on neurohormones, sharing the prize that year with Andrew Schally and Rosalyn Sussman Yalow.
Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat.
Releasing hormones and inhibiting hormones are hormones whose main purpose is to control the release of other hormones, either by stimulating or inhibiting their release. They are also called liberins and statins (respectively), or releasing factors and inhibiting factors. The principal examples are hypothalamic-pituitary hormones that can be classified from several viewpoints: they are hypothalamic hormones, they are hypophysiotropic hormones, and they are tropic hormones.
Neuroendocrinology is the branch of biology which studies the interaction between the nervous system and the endocrine system; i.e. how the brain regulates the hormonal activity in the body. The nervous and endocrine systems often act together in a process called neuroendocrine integration, to regulate the physiological processes of the human body. Neuroendocrinology arose from the recognition that the brain, especially the hypothalamus, controls secretion of pituitary gland hormones, and has subsequently expanded to investigate numerous interconnections of the endocrine and nervous systems.
The hypothalamic–pituitary–gonadal axis refers to the hypothalamus, pituitary gland, and gonadal glands as if these individual endocrine glands were a single entity. Because these glands often act in concert, physiologists and endocrinologists find it convenient and descriptive to speak of them as a single system.
A gonadotropin-releasing hormone agonist is a type of medication which affects gonadotropins and sex hormones. They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis, high testosterone levels in women, early puberty in children, as a part of transgender hormone therapy, and to delay puberty in transgender youth among other uses. It is also used in the suppression of spontaneous ovulation as part of controlled ovarian hyperstimulation, an essential component in IVF. GnRH agonists are given by injections into fat, as implants placed into fat, and as nasal sprays.
Gonadotropin-releasing hormone antagonists are a class of medications that antagonize the gonadotropin-releasing hormone receptor and thus the action of gonadotropin-releasing hormone (GnRH). They are used in the treatment of prostate cancer, endometriosis, uterine fibroids, female infertility in assisted reproduction, and for other indications.
Cetrorelix, or cetrorelix acetate, sold under the brand name Cetrotide, is an injectable gonadotropin-releasing hormone (GnRH) antagonist. A synthetic decapeptide, it is used in assisted reproduction to inhibit premature luteinizing hormone surges The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In addition, cetrorelix can be used to treat hormone-sensitive cancers of the prostate and breast and some benign gynaecological disorders. It is administered as either multiple 0.25 mg daily subcutaneous injections or as a single-dose 3 mg subcutaneous injection. The duration of the 3 mg single dose is four days; if human chorionic gonadotropin (hCG) is not administered within four days, a daily 0.25 mg dose is started and continued until hCG is administered.
Degarelix, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer.
Gonadotropin-releasing hormone (GnRH) insensitivity also known as Isolated gonadotropin-releasing hormone (GnRH)deficiency (IGD) is a rare autosomal recessive genetic and endocrine syndrome which is characterized by inactivating mutations of the gonadotropin-releasing hormone receptor (GnRHR) and thus an insensitivity of the receptor to gonadotropin-releasing hormone (GnRH), resulting in a partial or complete loss of the ability of the gonads to synthesize the sex hormones. The condition manifests itself as isolated hypogonadotropic hypogonadism (IHH), presenting with symptoms such as delayed, reduced, or absent puberty, low or complete lack of libido, and infertility, and is the predominant cause of IHH when it does not present alongside anosmia.
Elagolix, sold under the brand name Orilissa, is a gonadotropin-releasing hormone antagonist medication which is used in the treatment of pain associated with endometriosis in women. It is also under development for the treatment of uterine fibroids and heavy menstrual bleeding in women. The medication was under investigation for the treatment of prostate cancer and enlarged prostate in men as well, but development for these conditions was discontinued. Elagolix is taken by mouth once or twice per day. It can be taken for up to 6 to 24 months, depending on the dosage.
Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist medication which is used in the treatment of prostate cancer in men and uterine fibroids in women. It is also under development for use in the treatment of endometriosis. It is taken by mouth once per day.
A GnRH modulator, or GnRH receptor modulator, also known as an LHRH modulator or LHRH receptor modulator, is a type of medication which modulates the GnRH receptor, the biological target of the hypothalamic hormone gonadotropin-releasing hormone. They include GnRH agonists and GnRH antagonists. These medications may be GnRH analogues like leuprorelin and cetrorelix – peptides that are structurally related to GnRH – or small-molecules like elagolix and relugolix, which are structurally distinct from and unrelated to GnRH analogues.
Ozarelix is a peptide gonadotropin-releasing hormone antagonist which is or was under development by AEterna Zentaris Inc. and Spectrum Pharmaceuticals as a long-acting injection formulation for the treatment of prostate cancer. It has also been investigated for the treatment of endometriosis, but no development has been reported. The drug was previously under investigation for the treatment of benign prostatic hyperplasia and Alzheimer's disease as well, but development for these indications was discontinued. As of June 2015, it was in phase II clinical trials for prostate cancer. It seems to no longer be under development.
Gonadotropin-inhibitory hormone (GnIH) is a RFamide-related peptide coded by the NPVF gene in mammals.
Geoffrey Wingfield Harris (1913–1971) was a British physiologist and neuroendocrinologist. Often considered the "father of neuroendocrinology", he is best known for showing that the anterior pituitary is regulated by the hypothalamus via the hypophyseal portal system. His work established the principles for the 1977 Nobel Prize-winning discovery of hypothalamic hormones by Schally and Guillemin.